ID   KLH15_HUMAN             Reviewed;         604 AA.
AC   Q96M94; Q32MN3; Q8NDA3; Q96BM6; Q9C0I6;
DT   21-FEB-2006, integrated into UniProtKB/Swiss-Prot.
DT   21-FEB-2006, sequence version 2.
DT   28-JUN-2023, entry version 162.
DE   RecName: Full=Kelch-like protein 15;
GN   Name=KLHL15; Synonyms=KIAA1677;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Duodenum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 2-22; 47-75; 139-151; 214-235; 250-271; 277-297;
RP   356-450; 460-471; 533-542; 572-577 AND 582-602, FUNCTION, PATHWAY,
RP   INTERACTION WITH CUL3 AND RBBP8, SUBCELLULAR LOCATION, CLEAVAGE OF
RP   INITIATOR METHIONINE, MASS SPECTROMETRY, AND MUTAGENESIS OF ASN-132 AND
RP   ILE-136.
RX   PubMed=27561354; DOI=10.1038/ncomms12628;
RA   Ferretti L.P., Himmels S.F., Trenner A., Walker C., von Aesch C.,
RA   Eggenschwiler A., Murina O., Enchev R.I., Peter M., Freire R., Porro A.,
RA   Sartori A.A.;
RT   "Cullin3-KLHL15 ubiquitin ligase mediates CtIP protein turnover to fine-
RT   tune DNA-end resection.";
RL   Nat. Commun. 7:12628-12628(2016).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 84-604.
RC   TISSUE=Brain;
RX   PubMed=11214970; DOI=10.1093/dnares/7.6.347;
RA   Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:347-355(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 421-604.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   FUNCTION AS AN E3 UBIQUITIN-PROTEIN LIGASE, PATHWAY, AND INTERACTION WITH
RP   CUL3.
RX   PubMed=14528312; DOI=10.1038/ncb1056;
RA   Furukawa M., He Y.J., Borchers C., Xiong Y.;
RT   "Targeting of protein ubiquitination by BTB-Cullin 3-Roc1 ubiquitin
RT   ligases.";
RL   Nat. Cell Biol. 5:1001-1007(2003).
RN   [7]
RP   FUNCTION, INTERACTION WITH CUL3 AND PPP2R5B, HOMODIMERIZATION, AND
RP   MUTAGENESIS OF ASP-32; HIS-45; 72-ILE--LYS-75; ARG-318; 335-GLU--LEU-337
RP   AND GLU-371.
RX   PubMed=23135275; DOI=10.1074/jbc.m112.420281;
RA   Oberg E.A., Nifoussi S.K., Gingras A.C., Strack S.;
RT   "Selective proteasomal degradation of the B'beta subunit of protein
RT   phosphatase 2A by the E3 ubiquitin ligase adaptor Kelch-like 15.";
RL   J. Biol. Chem. 287:43378-43389(2012).
RN   [8]
RP   FUNCTION, PATHWAY, AND INTERACTION WITH PACMP.
RX   PubMed=35219381; DOI=10.1016/j.molcel.2022.01.020;
RA   Zhang C., Zhou B., Gu F., Liu H., Wu H., Yao F., Zheng H., Fu H., Chong W.,
RA   Cai S., Huang M., Ma X., Guo Z., Li T., Deng W., Zheng M., Ji Q., Zhao Y.,
RA   Ma Y., Wang Q.E., Tang T.S., Guo C.;
RT   "Micropeptide PACMP inhibition elicits synthetic lethal effects by
RT   decreasing CtIP and poly(ADP-ribosyl)ation.";
RL   Mol. Cell 82:1297-1312(2022).
RN   [9]
RP   INVOLVEMENT IN XLID103.
RX   PubMed=24817631; DOI=10.1002/ajmg.a.36602;
RA   Mignon-Ravix C., Cacciagli P., Choucair N., Popovici C., Missirian C.,
RA   Milh M., Megarbane A., Busa T., Julia S., Girard N., Badens C., Sigaudy S.,
RA   Philip N., Villard L.;
RT   "Intragenic rearrangements in X-linked intellectual deficiency: results of
RT   a-CGH in a series of 54 patients and identification of TRPC5 and KLHL15 as
RT   potential XLID genes.";
RL   Am. J. Med. Genet. A 164A:1991-1997(2014).
RN   [10]
RP   INVOLVEMENT IN XLID103.
RX   PubMed=25644381; DOI=10.1038/mp.2014.193;
RA   Hu H., Haas S.A., Chelly J., Van Esch H., Raynaud M., de Brouwer A.P.,
RA   Weinert S., Froyen G., Frints S.G., Laumonnier F., Zemojtel T., Love M.I.,
RA   Richard H., Emde A.K., Bienek M., Jensen C., Hambrock M., Fischer U.,
RA   Langnick C., Feldkamp M., Wissink-Lindhout W., Lebrun N., Castelnau L.,
RA   Rucci J., Montjean R., Dorseuil O., Billuart P., Stuhlmann T., Shaw M.,
RA   Corbett M.A., Gardner A., Willis-Owen S., Tan C., Friend K.L., Belet S.,
RA   van Roozendaal K.E., Jimenez-Pocquet M., Moizard M.P., Ronce N., Sun R.,
RA   O'Keeffe S., Chenna R., van Boemmel A., Goeke J., Hackett A., Field M.,
RA   Christie L., Boyle J., Haan E., Nelson J., Turner G., Baynam G.,
RA   Gillessen-Kaesbach G., Mueller U., Steinberger D., Budny B.,
RA   Badura-Stronka M., Latos-Bielenska A., Ousager L.B., Wieacker P.,
RA   Rodriguez Criado G., Bondeson M.L., Anneren G., Dufke A., Cohen M.,
RA   Van Maldergem L., Vincent-Delorme C., Echenne B., Simon-Bouy B.,
RA   Kleefstra T., Willemsen M., Fryns J.P., Devriendt K., Ullmann R.,
RA   Vingron M., Wrogemann K., Wienker T.F., Tzschach A., van Bokhoven H.,
RA   Gecz J., Jentsch T.J., Chen W., Ropers H.H., Kalscheuer V.M.;
RT   "X-exome sequencing of 405 unresolved families identifies seven novel
RT   intellectual disability genes.";
RL   Mol. Psychiatry 21:133-148(2016).
CC   -!- FUNCTION: Substrate-specific adapter for CUL3 E3 ubiquitin-protein
CC       ligase complex (PubMed:27561354, PubMed:14528312, PubMed:35219381).
CC       Acts as an adapter for CUL3 to target the serine/threonine-protein
CC       phosphatase 2A (PP2A) subunit PPP2R5B for ubiquitination and subsequent
CC       proteasomal degradation, thus promoting exchange with other regulatory
CC       subunits (PubMed:23135275). Acts as an adapter for CUL3 to target the
CC       DNA-end resection factor RBBP8/CtIP for ubiquitination and subsequent
CC       proteasomal degradation (PubMed:27561354, PubMed:35219381). Through the
CC       regulation of RBBP8/CtIP protein turnover, plays a key role in DNA
CC       damage response, favoring DNA double-strand repair through error-prone
CC       non-homologous end joining (NHEJ) over error-free, RBBP8-mediated
CC       homologous recombination (HR) (PubMed:27561354, PubMed:35219381).
CC       {ECO:0000269|PubMed:14528312, ECO:0000269|PubMed:23135275,
CC       ECO:0000269|PubMed:27561354, ECO:0000269|PubMed:35219381}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:14528312, ECO:0000269|PubMed:27561354,
CC       ECO:0000269|PubMed:35219381}.
CC   -!- SUBUNIT: Homodimer. Dimerization does not affect PPP2R5B-binding, but
CC       is required for its proteasomal degradation (PubMed:23135275).
CC       Interacts with CUL3 (PubMed:27561354, PubMed:14528312,
CC       PubMed:23135275). Directly interacts with PPP2R5B; this interaction
CC       leads to PPP2R5B proteasomal degradation (PubMed:23135275). Interacts
CC       with RBBP8/CtIP; this interaction leads to RBBP8 proteasomal
CC       degradation (PubMed:27561354). Interacts with PACMP micropeptide;
CC       interaction prevents ubiquitination and degradation of RBBP8/CtIP
CC       (PubMed:35219381). {ECO:0000269|PubMed:14528312,
CC       ECO:0000269|PubMed:23135275, ECO:0000269|PubMed:27561354,
CC       ECO:0000269|PubMed:35219381}.
CC   -!- INTERACTION:
CC       Q96M94; O15075: DCLK1; NbExp=2; IntAct=EBI-2510129, EBI-2684263;
CC       Q96M94; Q8N568: DCLK2; NbExp=3; IntAct=EBI-2510129, EBI-2930406;
CC       Q96M94; O88809: Dcx; Xeno; NbExp=2; IntAct=EBI-2510129, EBI-16724620;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:27561354}.
CC   -!- DISEASE: Intellectual developmental disorder, X-linked 103 (XLID103)
CC       [MIM:300982]: A form of intellectual disability, a disorder
CC       characterized by significantly below average general intellectual
CC       functioning associated with impairments in adaptive behavior and
CC       manifested during the developmental period. Intellectual deficiency is
CC       the only primary symptom of non-syndromic X-linked forms, while
CC       syndromic forms present with associated physical, neurological and/or
CC       psychiatric manifestations. {ECO:0000269|PubMed:24817631,
CC       ECO:0000269|PubMed:25644381}. Note=The disease may be caused by
CC       variants affecting the gene represented in this entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK057298; BAB71415.1; -; mRNA.
DR   EMBL; BC015415; AAH15415.1; -; mRNA.
DR   EMBL; BC109058; AAI09059.1; -; mRNA.
DR   EMBL; BC109059; AAI09060.1; -; mRNA.
DR   EMBL; AB051464; BAB21768.1; -; mRNA.
DR   EMBL; AL834313; CAD38983.1; -; mRNA.
DR   CCDS; CCDS35217.1; -.
DR   RefSeq; NP_085127.2; NM_030624.2.
DR   RefSeq; XP_006724581.1; XM_006724518.1.
DR   AlphaFoldDB; Q96M94; -.
DR   SMR; Q96M94; -.
DR   BioGRID; 123224; 91.
DR   IntAct; Q96M94; 46.
DR   MINT; Q96M94; -.
DR   STRING; 9606.ENSP00000332791; -.
DR   iPTMnet; Q96M94; -.
DR   PhosphoSitePlus; Q96M94; -.
DR   BioMuta; KLHL15; -.
DR   DMDM; 88909167; -.
DR   EPD; Q96M94; -.
DR   jPOST; Q96M94; -.
DR   MassIVE; Q96M94; -.
DR   PaxDb; Q96M94; -.
DR   PeptideAtlas; Q96M94; -.
DR   ProteomicsDB; 77318; -.
DR   Antibodypedia; 24558; 106 antibodies from 28 providers.
DR   DNASU; 80311; -.
DR   Ensembl; ENST00000328046.8; ENSP00000332791.8; ENSG00000174010.10.
DR   Ensembl; ENST00000684871.1; ENSP00000509774.1; ENSG00000174010.10.
DR   Ensembl; ENST00000685367.1; ENSP00000509439.1; ENSG00000174010.10.
DR   Ensembl; ENST00000689334.1; ENSP00000508713.1; ENSG00000174010.10.
DR   Ensembl; ENST00000693269.1; ENSP00000509509.1; ENSG00000174010.10.
DR   GeneID; 80311; -.
DR   KEGG; hsa:80311; -.
DR   MANE-Select; ENST00000328046.8; ENSP00000332791.8; NM_030624.3; NP_085127.2.
DR   AGR; HGNC:29347; -.
DR   CTD; 80311; -.
DR   DisGeNET; 80311; -.
DR   GeneCards; KLHL15; -.
DR   HGNC; HGNC:29347; KLHL15.
DR   HPA; ENSG00000174010; Tissue enhanced (bone).
DR   MalaCards; KLHL15; -.
DR   MIM; 300980; gene.
DR   MIM; 300982; phenotype.
DR   neXtProt; NX_Q96M94; -.
DR   OpenTargets; ENSG00000174010; -.
DR   PharmGKB; PA134934728; -.
DR   VEuPathDB; HostDB:ENSG00000174010; -.
DR   eggNOG; KOG4441; Eukaryota.
DR   GeneTree; ENSGT00940000159116; -.
DR   HOGENOM; CLU_004253_16_1_1; -.
DR   InParanoid; Q96M94; -.
DR   OMA; ADQWTIL; -.
DR   OrthoDB; 5472491at2759; -.
DR   PhylomeDB; Q96M94; -.
DR   TreeFam; TF328485; -.
DR   PathwayCommons; Q96M94; -.
DR   SignaLink; Q96M94; -.
DR   SIGNOR; Q96M94; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 80311; 10 hits in 818 CRISPR screens.
DR   ChiTaRS; KLHL15; human.
DR   GenomeRNAi; 80311; -.
DR   Pharos; Q96M94; Tbio.
DR   PRO; PR:Q96M94; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q96M94; protein.
DR   Bgee; ENSG00000174010; Expressed in adrenal tissue and 173 other tissues.
DR   ExpressionAtlas; Q96M94; baseline and differential.
DR   Genevisible; Q96M94; HS.
DR   GO; GO:0031463; C:Cul3-RING ubiquitin ligase complex; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:1990756; F:ubiquitin ligase-substrate adaptor activity; IDA:UniProtKB.
DR   GO; GO:2000042; P:negative regulation of double-strand break repair via homologous recombination; IDA:UniProtKB.
DR   GO; GO:0071630; P:nuclear protein quality control by the ubiquitin-proteasome system; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   CDD; cd18454; BACK_KLHL15; 1.
DR   CDD; cd18244; BTB_POZ_KLHL15; 1.
DR   Gene3D; 1.25.40.420; -; 1.
DR   Gene3D; 2.120.10.80; Kelch-type beta propeller; 1.
DR   InterPro; IPR011705; BACK.
DR   InterPro; IPR017096; BTB-kelch_protein.
DR   InterPro; IPR000210; BTB/POZ_dom.
DR   InterPro; IPR030597; BTB_POZ_KLHL15.
DR   InterPro; IPR015915; Kelch-typ_b-propeller.
DR   InterPro; IPR006652; Kelch_1.
DR   InterPro; IPR047030; KLHL15_BACK.
DR   InterPro; IPR011333; SKP1/BTB/POZ_sf.
DR   PANTHER; PTHR45632:SF12; KELCH-LIKE PROTEIN 15; 1.
DR   PANTHER; PTHR45632; LD33804P; 1.
DR   Pfam; PF07707; BACK; 1.
DR   Pfam; PF00651; BTB; 1.
DR   Pfam; PF01344; Kelch_1; 3.
DR   PIRSF; PIRSF037037; Kelch-like_protein_gigaxonin; 1.
DR   SMART; SM00875; BACK; 1.
DR   SMART; SM00225; BTB; 1.
DR   SMART; SM00612; Kelch; 5.
DR   SUPFAM; SSF117281; Kelch motif; 1.
DR   SUPFAM; SSF54695; POZ domain; 1.
DR   PROSITE; PS50097; BTB; 1.
PE   1: Evidence at protein level;
KW   Direct protein sequencing; Intellectual disability; Kelch repeat; Nucleus;
KW   Reference proteome; Repeat; Ubl conjugation pathway.
FT   CHAIN           1..604
FT                   /note="Kelch-like protein 15"
FT                   /id="PRO_0000223949"
FT   DOMAIN          31..98
FT                   /note="BTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00037"
FT   DOMAIN          133..237
FT                   /note="BACK"
FT   REPEAT          328..379
FT                   /note="Kelch 1"
FT   REPEAT          381..426
FT                   /note="Kelch 2"
FT   REPEAT          428..473
FT                   /note="Kelch 3"
FT   REPEAT          489..542
FT                   /note="Kelch 4"
FT   REPEAT          544..590
FT                   /note="Kelch 5"
FT   MUTAGEN         32
FT                   /note="D->A: Impaired homodimerization and PPP2R5B
FT                   proteasomal degradation. No effect on PPP2R5B-binding."
FT                   /evidence="ECO:0000269|PubMed:23135275"
FT   MUTAGEN         45
FT                   /note="H->L: No effect on homodimerization,
FT                   PPP2R5B-binding, nor on PPP2R5B proteasomal degradation."
FT                   /evidence="ECO:0000269|PubMed:23135275"
FT   MUTAGEN         72..75
FT                   /note="IHLK->AHAA: No effect on PPP2R5B-binding, nor on
FT                   homodimerization, but loss of CUL3 recruitment to the
FT                   KLHL15/PPP2R5B complex and impaired PPP2R5B proteasomal
FT                   degradation."
FT                   /evidence="ECO:0000269|PubMed:23135275"
FT   MUTAGEN         132
FT                   /note="N->A: Decreased interaction with CUL3, especially
FT                   with the neddylated form of CUL3."
FT                   /evidence="ECO:0000269|PubMed:27561354"
FT   MUTAGEN         136
FT                   /note="I->A: Decreased interaction with CUL3, especially
FT                   with the neddylated form of CUL3."
FT                   /evidence="ECO:0000269|PubMed:27561354"
FT   MUTAGEN         318
FT                   /note="R->E: Impaired PPP2R5B-binding and proteasomal
FT                   degradation."
FT                   /evidence="ECO:0000269|PubMed:23135275"
FT   MUTAGEN         335..337
FT                   /note="EEL->REA: Impaired PPP2R5B-binding and proteasomal
FT                   degradation."
FT                   /evidence="ECO:0000269|PubMed:23135275"
FT   MUTAGEN         371
FT                   /note="E->R: Impaired PPP2R5B-binding and proteasomal
FT                   degradation."
FT                   /evidence="ECO:0000269|PubMed:23135275"
FT   MUTAGEN         386
FT                   /note="G->C: Decreased interaction with RBBP8 and complete
FT                   loss of nuclear localization, found exclusively in the
FT                   cytoplasm."
FT                   /evidence="ECO:0000269|PubMed:27561354"
FT   MUTAGEN         552
FT                   /note="Y->A: Decreased interaction with RBBP8 and increased
FT                   DNA-end resection and homologous recombination frequency
FT                   following DNA double-strand breaks compared to the
FT                   wild-type protein. No significant change in subcellular
FT                   location."
FT                   /evidence="ECO:0000269|PubMed:27561354"
FT   CONFLICT        297
FT                   /note="K -> E (in Ref. 1; BAB71415)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   604 AA;  69775 MW;  E37606E8AE367C83 CRC64;
     MAGDVEGFCS SIHDTSVSAG FRALYEEGLL LDVTLVIEDH QFQAHKALLA TQSDYFRIMF
     TADMRERDQD KIHLKGLTAT GFSHVLQFMY YGTIELSMNT VHEILQAAMY VQLIEVVKFC
     CSFLLAKICL ENCAEIMRLL DDFGVNIEGV REKLDTFLLD NFVPLMSRPD FLSYLSFEKL
     MSYLDNDHLS RFPEIELYEA VQSWLRHDRR RWRHTDTIIQ NIRFCLMTPT SVFEKVKTSE
     FYRYSRQLRY EVDQALNYFQ NVHQQPLLDM KSSRIRSAKP QTTVFRGMIG HSMVNSKILL
     LKKPRVWWEL EGPQVPLRPD CLAIVNNFVF LLGGEELGPD GEFHASSKVF RYDPRQNSWL
     QMADMSVPRS EFAVGVIGKF IYAVAGRTRD ETFYSTERYD ITNDKWEFVD PYPVNKYGHE
     GTVLNNKLFI TGGITSSSTS KQVCVFDPSK EGTIEQRTRR TQVVTNCWEN KSKMNYARCF
     HKMISYNGKL YVFGGVCVIL RASFESQGCP STEVYNPETD QWTILASMPI GRSGHGVTVL
     DKQIMVLGGL CYNGHYSDSI LTFDPDENKW KEDEYPRMPC KLDGLQVCNL HFPDYVLDEV
     RRCN
//
